DDInter944 DDInter596
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Cabazitaxel {u} (Compound) treats {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethambutol
Ethambutol {u} (Compound) causes {v} (Side Effect) Neutropenia
Neutropenia {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Cabazitaxel {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carfilzomib
Carfilzomib {u} (Compound) binds {v} (Gene) PSMB10
PSMB10 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) S100A13
S100A13 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Interferon alfa-n1 {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) downregulates {v} (Gene) USP22
USP22 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) treats prostate cancer (Disease) and prostate cancer (Disease) is treated by Doxorubicin (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ethambutol and Ethambutol (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin (Compound) resembles Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib (Compound) binds PSMB10 (Gene) and PSMB10 (Gene) is upregulated by Doxorubicin (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) downregulates S100A13 (Gene) and S100A13 (Gene) is upregulated by Doxorubicin (Compound)
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Interferon alfa-n1 may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) downregulates USP22 (Gene) and USP22 (Gene) is downregulated by Doxorubicin (Compound)